A5011521807- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Nonmelanoma Skin Cancer Studies
- CAR-T cell therapy research
- Microbial Inactivation Methods
- Thyroid Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Cutaneous lymphoproliferative disorders research
- Immune cells in cancer
- Cell Image Analysis Techniques
- Colorectal Cancer Treatments and Studies
- Cancer, Hypoxia, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Toxin Mechanisms and Immunotoxins
- Adrenal and Paraganglionic Tumors
- Advanced Biosensing Techniques and Applications
- Allergic Rhinitis and Sensitization
- Microfluidic and Bio-sensing Technologies
- AI in cancer detection
- Thyroid and Parathyroid Surgery
- Monoclonal and Polyclonal Antibodies Research
- Optical Coherence Tomography Applications
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2016-2025
Cancer Institute (WIA)
2006-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2022
University of Cambridge
2021
Long Island Skin Cancer and Dermatologic Surgery
2018
Hospitales Nisa
2016
National Cancer Institute
2006-2013
Tumour Institute of Tuscany
2000-2012
Melanoma Institute Australia
2010
Istituto Oncologico Veneto
2009
Purpose The prevalence of BRAF, NRAS, and p16CDKN2A mutations during melanoma progression remains inconclusive. We investigated the distribution in these genes different tissues. Patients Methods In all, 291 tumor tissues from 132 patients with were screened. Paired samples primary melanomas (n = 102) synchronous or asynchronous metastases same 165) included. Tissue underwent mutation analysis (automated DNA sequencing). Secondary lesions included lymph nodes 84), skin 36), visceral 25),...
Previous studies have suggested that elevated neutrophil-to-lymphocyte ratio (NLR) is prognostic for worse outcomes in patients with a variety of solid cancers, including those treated immune checkpoint inhibitors.This was retrospective analysis 97 consecutive stage IV melanoma who were nivolumab. Baseline NLR and derived (d) calculated and, along other characteristics, correlated progression-free survival (PFS) overall (OS) univariate multivariate analyses. The best cutoff values dNLR using...
Cancer radiotherapy (RT) may induce what is referred to as the "abscopal effect," a regression of non-irradiated metastatic lesions distant from primary tumor site directly subject irradiation. This clinical response rare, but has been surmised be an immune-mediated phenomenon, suggesting that immunotherapy and RT could potentially synergize. Here, we report outcome patients with advanced melanoma treated immune checkpoint blockade monoclonal antibody antagonist, ipilimumab followed by RT....
The resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators implement novel clinical trials which combine immunotherapy with different modalities. Moreover is also important investigate mechanisms regulate dynamic expression PD-L1 on tumor cells and PD-1 T in order identify predictive biomarkers response. COX-2 currently investigated as a major player progression several type malignancies including melanoma. In present study we potential relationship...
Abstract Purpose: The chemokine receptor CXCR4 was identified as an independent predictor of poor prognosis in primary melanoma. aim the study to investigate role human melanoma metastases. Experimental Design: expression evaluated metastases and metastatic cell lines through immunohistochemistry, immunoblotting, immunofluorescence, reverse transcription-PCR. function tested presence ligand, CXCL12, induction extracellular signal-regulated kinase-1 -2 (Erk-1 -2) phosphorylation,...
Melanoma is responsible for most skin cancer-related deaths and one of the common cancers diagnosed in young adults. In melanoma, tumors can become established by activation negative regulator cytotoxic T lymphocytes (CTLs), CTL antigen-4 (CTLA-4). Ipilimumab blocks interaction CTLA-4 with CD80/CD86 augments T-cell proliferation. electrochemotherapy (ECT), local application short high-voltage pulses renders cell membranes transiently permeable to chemotherapeutic drugs. The combination...
<h3>Importance</h3> Sentinel lymph node (SLN) biopsy is a standard staging procedure for cutaneous melanoma. Regional disease control clinically important therapeutic goal of surgical intervention, including nodal surgery. <h3>Objective</h3> To determine how frequently SLN without completion dissection (CLND) results in long-term regional patients with metastases. <h3>Design, Setting, and Participants</h3> The second Multicenter Selective Lymphadenectomy Trial (MSLT-II), prospective...
Abstract Background Identifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma. Methods A retrospective study was carried out unresectable/metastatic melanoma (stage IIIb–IV), treated anti-PD-1 first line setting, better explore role and timing of neutrophil/lymphocyte ratio (NLR) as potential biomarker response. The relationship NLR inflammation-immune mediators underlying negative effect raising during immunotherapy, have been...
Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% patients relapsing within 5 years. For lesions refractory to elective treatments, electrochemotherapy (ECT) involving electroporation combined antineoplastic drug treatment appears be new potential option. This study was undertaken analyze the short- long-term responses treated ECT intravenous injection bleomycin in melanoma in-transit disease or distant metastases.Between June...
We investigated whether the nonsentinel lymph node (NSLN) status in patients with melanoma improves prognostic accuracy of common staging features; then we formulated a proposal for including NSLN current system.We retrospectively collected clinicopathologic data 1,538 positive SLN who underwent completion dissection (CLND) at nine Italian centers. Multivariable Cox regression survival analysis was used to identify independent factors. Literature meta-analysis summarize available evidence on...
Background: Tumor microenvironment may have a key role in providing immunological markers that can help predict clinical response to treatment with checkpoint inhibitors. We investigated whether the baseline expression of PD-L1 advanced melanoma patients treated ipilimumab correlate outcome. Methods: was assessed 114 and, cohort 77 patients, comprehensive assessment using multispectral imaging assess presence and distribution CD3+, CD8+, CD163+, FOXP3+ PD-L1+ cells inside at periphery tumor...
Although the number of excised lymph nodes (LNs) represents a quality assurance measure in lymphadenectomy for many solid tumors, minimum LNs to be dissected has not been established melanoma.To investigate distribution large patient series (N = 2526) identify values that may serve as benchmarks monitoring patients with melanoma.A retrospective multicenter study was conducted (1992-2010) tertiary referral centers treatment cutaneous melanoma. Medical records on 2526 who underwent regional LN...
Extensive squamous cell carcinoma has few therapeutic options. In such cases, electrochemotherapy involving electroporation combined with antineoplastic drug appears to be a new potential option and may considered as an alternative treatment. The aim of this retrospective single-center study was evaluate efficacy in treatment locally advanced stage III carcinoma, which surgical procedures would have entailed wide tissue sacrifice. Clinical features, response, adverse effects were evaluated...
Abstract Treatment duration with checkpoint inhibitors must be optimized to prevent unjustified toxicity, but evidence for the management of cutaneous squamous cell carcinoma is lacking. A retrospective study was performed evaluate survival patients (CSCC) who discontinued cemiplimab due different causes and without progression. Among 95 CSCC received cemiplimab, 22 (23%) immunotherapy other than progression, such as comorbidities, complete response or lack compliance (group that before...